Andrea Franson, M.D., M.S., received an $800,000 “A” Award grant from Alex’s Lemonade Stand Foundation for Childhood Cancer to translate an approach developed at Rogel Cancer Center into a phase 1 clinical trial for children with high-grade glioma.
Metabolites called nucleotides are the building blocks of DNA and can impact cancer’s sensitivity or resistance to chemotherapy and radiation in brain cancer. Recent findings show how a specific nucleotide metabolite, called GTP, controls responses to radiation and chemotherapy in an unexpected way.
Researchers at the University of Michigan Health Rogel Cancer Center are exploiting a unique biological feature of glioblastoma to gain a better understanding of how this puzzling brain cancer develops and how to target new treatments against it. The team developed human and mouse models of glioblastoma oncostreams and examined multiple factors in the tumor microenvironment that could impact how oncostreams develop and how to reverse them.
An inter-departmental group of researchers at the Rogel Cancer Center received a grant from the National Cancer Institute to further research on radiosensitization, the process of making tumors more vulnerable to radiation treatment.
MENU